PE is characterized by ejaculation prior to, or soon after, vaginal penetration with minimal stimulation, with the male having no control over ejaculation. Definitions have been published by the International Society for Sexual Medicine and in the Diagnostic Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR),
| Country | Legal Status | Purchase Restrictions | Online Purchase Allowed? |
|---|---|---|---|
| USA | Prescription-required | Doctor consultation needed | Yes |
| UK | Prescription-required | Prescription needed | Yes |
| Germany | Prescription-required | Prescription mandatory | Yes |
| India | Often OTC | Can be bought without prescription | Yes |
| Canada | Prescription-required | Medical prescription necessary | Yes |
with the key point being the uncontrolled brevity of sexual intercourse.6–8 The negative consequences of PE are significant, and affect both the male and female partner.
This study has been sponsored by Neutec Ar-Ge San & Tic AS (Turkey). The authors declare that they have no conflict of interest. Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction—DAP-SPEED Study. What Is the Role of Ejaculation Latency in the Diagnosis of Premature Ejaculation and Does the Ejaculation Latency Threshold Matter?
Conservative Non-surgical Options for Erectile Dysfunction Current Urology Reports (2023) The role of tyrosine hydroxylase within dapoxetine-assisted therapy against premature ejaculation Molecular Biology Reports (2023) Current and emerging treatment options for premature ejaculation Nature Reviews Urology (2022) Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity Nature Reviews Urology (2021) 058 The Efficacy and Safety of Dapoxetine / Sildenafil Combination Therapy in the Treatment of Men with Premature Ejaculation and Erectile Dysfunction – DAP-SPEED Study - ScienceDirect Please enable JavaScript to use all the features on this page. 058 The Efficacy and Safety of Dapoxetine / Sildenafil Combination Therapy in the Treatment of Men with Premature Ejaculation and Erectile Dysfunction – DAP-SPEED Study Author links open overlay panelM.Tuken1, M.G.Culha2, E.C.Serefoglu3 Premature ejaculation (PE) and erectile dysfunction (ED) are the most prevalent sexual disorders in men. ED is commonly reported among patients with PE.Although recent guidelines recommend to treat ED first in men with both PE and ED, this recommendation is not based on evidence and there is limited data about the efficacy and safety of dapoxetin / sildenafil combination therapy for these patients. The aim of this study is to evaluate the clinical efficacy and safety of the dapoxetine / sildenafil combination (Dapoxil 30/50 mg film-coated tablet) in the treatment of patients with PE and concomitant ED. In a single-center, single-arm, open-label clinical study, 74 patients with lifelong / acquired PE and ED were included between October 2016 to September 2017.Patients received on demand dapoxetine / sildenafil (30/50 mg film-coated tablets) 1-3 hours before sexual intercourse for 4 weeks (2 days a week and no more than once a day).
All patients were instructed to record their intravaginal ejaculatory latency time (IELT). They were also instructed to complete Premature Ejaculation Diagnostic The study was completed with 53 patients (71.62%). Mean age of the patients was 45.32±10.05. Before the treatment, geometric mean IELT of the patients was 22.72±15.16 seconds, mean PEDT score was 16.85±2.42, mean PEP score was 3.36±1.12and IIEF-EF score was 13.17±3.33. At the end of the 4-week treatment period, statistically significant improvements were observed in the mean IELTs, PEP and IIEF-EF scores compared to the patients' pre-treatment values (69.47±103.34;p<0.001, 9.92±2.36;p<0.001, The dapoxetine/ sildenafil combination therapy significantly improves the IELT values and patient reported outcome measures of PE patients who also suffer from ED. As well as obvious sexual dissatisfaction, the condition can cause personal distress, low self-esteem, and interpersonal difficulty.5,9–11 Dapoxetine
| Reviewer | Effectiveness | Side Effects | Satisfaction Level | Comments |
|---|---|---|---|---|
| User A | Very effective | Mild headache | 5/5 | Works well for both ED and PE |
| User B | Moderately effective | Dizziness | 4/5 | Slight dizziness but manageable |
| User C | Less effective | None reported | 3/5 | Needs higher dose for better results |
| User D | Effective | Nausea at start | 4/5 | Side effects decrease over time |
belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs) which are frequently used to treat depression.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 50mg | 10 Pills | 26.87€ 25.59€ | |
| Viagra Original | 100mg | 92 + 4 Pills | 362.88€ 345.60€ | |
| Viagra Soft Tabs | 100mg | 270 + 10 Pills | 419.95€ 399.95€ | |
| Viagra Super Active | 100mg | 180 + 20 Pills | 280.97€ 267.59€ | |
| Viagra Generic | 50mg | 120 + 6 Pills | 129.64€ 123.47€ | |
| Viagra Original | 100mg | 8 Pills | 59.84€ 56.99€ | |
| Viagra Professional | 100mg | 180 + 4 Pills | 337.30€ 321.24€ | |
| Viagra Generic | 100mg | 120 + 6 Pills | 149.50€ 142.38€ | |
| Viagra Professional | 100mg | 120 + 4 Pills | 262.83€ 250.31€ | |
| Viagra Super Active | 100mg | 360 + 30 Pills | 470.93€ 448.50€ | |
| Viagra Professional | 100mg | 90 + 2 Pills | 207.09€ 197.23€ | |
| Viagra Generic | 200mg | 30 + 2 Pills | 83.07€ 79.11€ | |
| Viagra Soft Tabs | 100mg | 180 + 10 Pills | 314.95€ 299.95€ | |
| Viagra Oral Jelly | 100mg | 21 Sachets | 78.66€ 74.91€ |
Prior to the availability of dapoxetine, psychotherapy (eg, cognitive behavior therapy) was widely used to treat PE.
Further studies are needed to evaluate long-term efficacy and health economics. The unique pharmacology of dapoxetine makes it ideal for on-demand dosing, and the clinical evidence shows dapoxetine to be an efficacious and tolerable treatment for lifelong and acquired PE. Keywords: dapoxetine, intravaginal ejaculatory latency time, patient-reported outcomes, premature ejaculation Dapoxetine (PriligyTM, Johnson and Johnson, Raritan, NJ) is the first and only product licensed for the treatment of premature ejaculation (PE) in men aged 18–64 years. At present, dapoxetine is licensed in ten countries, including several countries in Europe, and Mexico, South Korea, and New Zealand.1,2 PE is the most common sexual dysfunction in men, with a global prevalence estimated to be between 20% and 40%.3–5 The uncertainty about prevalence figures is due to the intimate nature of the condition and, until recently, the lack of a universal evidence-based definition. It is probable that many men do not admit to having the condition and do not seek medical advice. More recently, several SSRIs (other than dapoxetine) have been used off-label to treat PE.12,13 These SSRIs were not developed to treat PE,12 in contrast with dapoxetine
which was specifically developed for this purpose and has a different pharmacological profile to the other SSRIs,14–17 with properties making it suitable for on-demand dosing.1 The aims
Although several side effects were reported, these were mild and reversible. Premature ejaculation (PE) is liquid viagra a major issue in male sexual health. The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a negative impact on interpersonal relationships. Historically, it has been treated with cognitive therapy, behavioral methods, and off-label use of selective serotonin reuptake inhibitors usually used to treat depression and other psychological disorders.
Dapoxetine is a selective serotonin reuptake inhibitor specifically designed to treat PE. This paper reviews the current evidence for use of dapoxetine in the treatment of PE in adult men. There is substantial evidence that dapoxetine 30 mg or 60 mg taken “on-demand” results in a significant increase in intravaginal ejaculatory latency time when compared with placebo. Patient-reported outcomes are clearly improved relative to placebo following dapoxetine therapy, indicating greater control over ejaculation, more satisfaction with intercourse, less ejaculation-related distress, and, importantly, significantly reduced interpersonal difficulty. These data were supported by consistent reports of improvement in Clinical Global Impression of change in PE following treatment with dapoxetine. of this article are to review the current evidence for use of dapoxetine in the treatment of PE, including the ability of the drug to not
only increase time to ejaculation post-penetration, termed intravaginal ejaculatory latency time (IELT), but
Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. McMahon CG, Porst H. Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. Mattos RM, yellow viagra pill Marmo Lucon A, Srougi M.
Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. Corona G, Rastrelli G, Limoncin E, Sforza A, Jannini EA, Maggi M. Interplay between premature ejaculation and erectile dysfunction: a systematic review and meta-analysis. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P.
Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. The authors would like to thank Neutec Ar-Ge San & Tic AS Clinical Research Department for their cooperation. also to improve patient self-esteem, satisfaction with sexual intercourse, and perceived control over ejaculation.
Men C, Yu L, Yuan H, Cui Y. Efficacy and safety of phosphodiesterase type 5 inhibitors on primary premature ejaculation in men receiving selective serotonin reuptake inhibitors therapy: a systematic review and meta-analysis. Asimakopoulos AD, Miano R, Finazzi Agro E, Vespasiani G, Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review.
Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Turkish validation of the premature ejaculation diagnostic tool and its association with intravaginal ejaculatory latency time. The comparison of premature ejaculation assessment questionnaires and their sensitivity for the four premature ejaculation syndromes: results from the Turkish society of andrology sexual health survey. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. An empirical operationalization study of DSM-IV diagnostic criteria for premature ejaculation. A tutorial on pilot studies: the what, why and how. Advances in understanding and treating premature ejaculation.